Page last updated: 2024-11-05

thalidomide and Plasmacytoma

thalidomide has been researched along with Plasmacytoma in 49 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Plasmacytoma: Any discrete, presumably solitary, mass of neoplastic PLASMA CELLS either in BONE MARROW or various extramedullary sites.

Research Excerpts

ExcerptRelevanceReference
"In conclusion, pomalidomide and dexamethasone has limited efficacy in patients with advanced MM and soft-tissue plasmacytomas."7.91Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma. ( Abella, E; Bladé, J; Cabezudo, E; Cibeira, MT; Clapés, V; Escoda, L; Fernández de Larrea, C; García-Guiñón, A; Gironella, M; Granell, M; Isola, I; Jiménez-Segura, R; López-Pardo, J; Oriol, A; Rosiñol, L; Soler, JA; Tovar, N, 2019)
"Thalidomide and its analogs have been extensively studied in patients with multiple myeloma."7.73Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide. ( Carbonell, AL; del Giglio, A; Manhani, AR; Mitteldorf, CA; Weinschenker, P, 2005)
"Thalidomide (Thd), a potent teratogen, was shown to have therapeutic potential in cancer, primarily in multiple myeloma (MM), yet its mechanism of action has not been elucidated."7.72Thalidomide down-regulates transcript levels of GC-rich promoter genes in multiple myeloma. ( Drucker, L; Lahav, M; Lishner, M; Radnay, J; Shapiro, H; Tohami, T; Uziel, O; Yarkoni, S, 2003)
"We report two patients who were treated with thalidomide for resistant multiple myeloma (MM) and developed extramedullary plasmacytomas despite a good response in the bone marrow."7.71Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma. ( Avigdor, A; Ben-Bassat, I; Hardan, I; Levi, I; Raanani, P, 2001)
"The pathogenesis of POEMS syndrome is not well understood, but overproduction of vascular endothelial growth factor (VEGF), probably secreted by plasmacytoma, may be responsible for most of its characteristic symptoms."6.44[New strategy of treatment for POEMS syndrome--autologous peripheral blood stem cell transplantation and thalidomide therapy]. ( Kuwabara, S, 2008)
"Intracerebral plasmacytoma is an extremely rare disease for which no treatment protocol has been established."5.46Metastatic Intracerebral Plasmacytoma Treated with Radiation and Thalidomide, Dexamethasone with Cyclophosphamide Chemotherapy. ( Kang, SH; Kim, TS; Ko, SJ; Park, KJ, 2017)
"A 74-year-old man with multiple myeloma was refractory to melphalan/prednisolone (MP), high-dose dexamethasone and VAD chemotherapy."5.35Refractory plasmablastic type myeloma with multiple extramedullary plasmacytomas and massive myelomatous effusion: remarkable response with a combination of thalidomide and dexamethasone. ( Kakimoto, T; Mihara, A; Nakazato, T; Sanada, Y; Suzuki, K, 2009)
"Thalidomide has antiangiogenic and immunomodulatory effects, mediated by several cytokines such as vascular endothelial growth factor (VEGF), fibroblastic growth factor (FGF-2), hepatocyte growth factor (HGF), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha)."5.32Response to thalidomide in multiple myeloma: impact of angiogenic factors. ( Arenillas, L; Aymerich, M; Bladé, J; Cibeira, MT; Cid, MC; Esteve, J; Filella, X; Montserrat, E; Rosiñol, L; Rozman, M; Segarra, M, 2004)
" The tandem transplant trial, Total Therapy 2, enrolled 668 patients, who were randomised up-front to thalidomide (THAL) or no THAL; 56 patients were identified as having had, for at least 6 months prior to initiation of therapy, monoclonal gammopathy of undetermined significance (MGUS, n = 21), smouldering MM (SMM, n = 22) or solitary plasmacytoma of bone (SPC, n = 13)."5.12Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. ( Anaissie, E; Arzoumanian, V; Barlogie, B; Bolejack, V; Crowley, J; Epstein, J; Hollmig, K; Krishna, S; Pineda-Roman, M; Shaughnessy, JD; van Rhee, F; Walker, R; Zangari, M, 2007)
"In conclusion, pomalidomide and dexamethasone has limited efficacy in patients with advanced MM and soft-tissue plasmacytomas."3.91Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma. ( Abella, E; Bladé, J; Cabezudo, E; Cibeira, MT; Clapés, V; Escoda, L; Fernández de Larrea, C; García-Guiñón, A; Gironella, M; Granell, M; Isola, I; Jiménez-Segura, R; López-Pardo, J; Oriol, A; Rosiñol, L; Soler, JA; Tovar, N, 2019)
"Patients with complicated extramedullary plasmacytomas at the time of diagnosis received traditional treatment, including vincristine adriamycin, dexamethasone, medphalan, prednisone, thalidomide and bortezomib."3.75[A clinical analysis of 25 cases of multiple myeloma complicated by extramedullary plasmacytomas]. ( Chen, SL; Zhong, YP, 2009)
"Thalidomide and its analogs have been extensively studied in patients with multiple myeloma."3.73Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide. ( Carbonell, AL; del Giglio, A; Manhani, AR; Mitteldorf, CA; Weinschenker, P, 2005)
"Thalidomide (Thd), a potent teratogen, was shown to have therapeutic potential in cancer, primarily in multiple myeloma (MM), yet its mechanism of action has not been elucidated."3.72Thalidomide down-regulates transcript levels of GC-rich promoter genes in multiple myeloma. ( Drucker, L; Lahav, M; Lishner, M; Radnay, J; Shapiro, H; Tohami, T; Uziel, O; Yarkoni, S, 2003)
"We report two patients who were treated with thalidomide for resistant multiple myeloma (MM) and developed extramedullary plasmacytomas despite a good response in the bone marrow."3.71Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma. ( Avigdor, A; Ben-Bassat, I; Hardan, I; Levi, I; Raanani, P, 2001)
"Acquired hemophilia A is a rare autoimmune disease with clinically often significant bleeding diathesis resulting from circulating autoantibodies inhibiting coagulation factor VIII."2.66Acquired hemophilia A and plasma cell neoplasms: a case report and review of the literature. ( Andres, M; Angelillo-Scherrer, A; Dickenmann, M; Jalowiec, KA; Kremer Hovinga, JA; Musa, A; Rovó, A; Taleghani, BM, 2020)
"Primary plasmacytomas are localized proliferations of clonal plasma cells occurring in the absence of a systemic plasma cell dyscrasia such as multiple myeloma."2.61Primary extramedullary plasmacytoma with diffuse lymph node involvement: a case report and review of the literature. ( Abdul-Hay, M; Naymagon, L, 2019)
"The pathogenesis of POEMS syndrome is not well understood; however overproduction of vascular endothelial growth factor (VEGF), probably secreted by plasmacytoma, may be responsible for most of the characteristic symptoms, including neuropathy."2.44[Electrophysiologic aspects of Crow-Fukase (POEMS) syndrome--significance in early diagnosis and insights into the pathophysiology]. ( Misawa, S, 2008)
"The pathogenesis of POEMS syndrome is not well understood, but overproduction of vascular endothelial growth factor (VEGF), probably secreted by plasmacytoma, may be responsible for most of its characteristic symptoms."2.44[New strategy of treatment for POEMS syndrome--autologous peripheral blood stem cell transplantation and thalidomide therapy]. ( Kuwabara, S, 2008)
"Intracerebral plasmacytoma is an extremely rare disease for which no treatment protocol has been established."1.46Metastatic Intracerebral Plasmacytoma Treated with Radiation and Thalidomide, Dexamethasone with Cyclophosphamide Chemotherapy. ( Kang, SH; Kim, TS; Ko, SJ; Park, KJ, 2017)
"Progression to multiple myeloma is the most common pattern of relapse."1.46Metachronous solitary plasmacytoma. ( Khosa, R; Nangia, S; Seth, S, 2017)
"Plasmacytomas are monoclonal plasma cell tumors."1.42Diplopia and variable ptosis as the sole initial findings in a case of orbital plasmacytoma and multiple myeloma. ( Galea, M; McMillan, N; Weir, C, 2015)
" Xenografts acquired resistance to two generations of immunomodulatory drugs (IMiDs; lenalidomide and pomalidomide) in combination with dexamethasone, that was reversible after a wash-out period."1.42In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. ( Bjorklund, CC; Corchete, LA; Couto, S; Delgado, M; Díaz-Rodríguez, E; Fernández-Lázaro, D; Garayoa, M; García-Gómez, A; Gutiérrez, NC; López-Corral, L; Mateos, MV; Montero, JC; Ocio, EM; Paíno, T; Pandiella, A; San-Miguel, JF; San-Segundo, L; Wang, M, 2015)
"The patient was diagnosed with multiple myeloma and received chemotherapy with thalidomide, cyclophosphamide and dexamethasone."1.39Multiple myeloma presenting as plasmacytoma of the jaws showing prominent bone formation during chemotherapy. ( An, CH; An, SY; Choi, KS; Heo, MS, 2013)
"Plasmacytoma is a rare B-lymphocyte neoplastic disorder that usually presents as the generalized disease multiple myeloma."1.36Solitary extramedullary plasmacytoma of the bladder: a case report and literature. ( Egner, JR; Khaliq, W; Konchanin, RP; Sapiente, RA; Uzoaru, I, 2010)
"Cranial nerve involvement in multiple myeloma and solitary plasmacytoma is rare."1.36Cranial nerve palsy in multiple myeloma and solitary plasmacytoma. ( Kashyap, R; Kumar, R; Kumar, S, 2010)
"A 74-year-old man with multiple myeloma was refractory to melphalan/prednisolone (MP), high-dose dexamethasone and VAD chemotherapy."1.35Refractory plasmablastic type myeloma with multiple extramedullary plasmacytomas and massive myelomatous effusion: remarkable response with a combination of thalidomide and dexamethasone. ( Kakimoto, T; Mihara, A; Nakazato, T; Sanada, Y; Suzuki, K, 2009)
"These cases of unconventional disease recurrence are likely to be seen due to sub-clinical seeding of tumour cells suggestive of the presence of an extramedullary (EM) clone of plasma cells with a high degree of chemoresistance."1.33Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma. ( Apperley, JF; Basu, S; Milne, AE; Rahemtulla, A; Rezvani, K; Rose, PE; Samson, D; Scott, GL; Terpos, E, 2005)
"Thalidomide has antiangiogenic and immunomodulatory effects, mediated by several cytokines such as vascular endothelial growth factor (VEGF), fibroblastic growth factor (FGF-2), hepatocyte growth factor (HGF), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha)."1.32Response to thalidomide in multiple myeloma: impact of angiogenic factors. ( Arenillas, L; Aymerich, M; Bladé, J; Cibeira, MT; Cid, MC; Esteve, J; Filella, X; Montserrat, E; Rosiñol, L; Rozman, M; Segarra, M, 2004)

Research

Studies (49)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's19 (38.78)29.6817
2010's25 (51.02)24.3611
2020's5 (10.20)2.80

Authors

AuthorsStudies
Oyama, T1
Taoka, K1
Chiba, A1
Masamoto, Y1
Ikemura, M1
Honda, A1
Maki, H1
Kurokawa, M1
Lin, Y1
He, J1
Li, F1
Gu, X1
Oka, S1
Ono, K1
Nohgawa, M1
Mouhieddine, TH1
Barlogie, B2
Teruya-Feldstein, J1
Jalowiec, KA1
Andres, M1
Taleghani, BM1
Musa, A1
Dickenmann, M1
Angelillo-Scherrer, A1
Rovó, A1
Kremer Hovinga, JA1
Kim, TS1
Ko, SJ1
Park, KJ1
Kang, SH1
Al-Mayoof, O1
Al Sughaiyer, H1
Abuomar, W1
Khan, M1
Khosa, R1
Seth, S1
Nangia, S1
Quilodrán, JA1
Peña, C1
Valladares, X1
de Assis Pereira Hansen, C1
Filho, JS1
de Mattos Nascimento, M1
Alves, FA1
Neotti, T1
D Almeida Costa, F1
Jiménez-Segura, R1
Granell, M1
Gironella, M1
Abella, E1
García-Guiñón, A1
Oriol, A1
Cabezudo, E1
Clapés, V1
Soler, JA1
Escoda, L1
López-Pardo, J1
Fernández de Larrea, C1
Cibeira, MT2
Tovar, N1
Isola, I1
Bladé, J3
Rosiñol, L3
Naymagon, L1
Abdul-Hay, M1
An, SY1
An, CH1
Choi, KS1
Heo, MS1
Sekiguchi, Y1
Asahina, T1
Shimada, A1
Imai, H1
Wakabayashi, M1
Sugimoto, K1
Nakamura, N1
Sawada, T1
Komatsu, N1
Noguchi, M1
Smith, D1
Stevens, J1
Quinn, J1
Cavenagh, J1
Ingram, W1
Yong, K1
Galea, M1
McMillan, N1
Weir, C1
Devoe, CE1
Li, JY1
Demopoulos, AM1
Sharman, JP1
Chmielecki, J1
Morosini, D1
Palmer, GA1
Ross, JS1
Stephens, PJ1
Stafl, J1
Miller, VA1
Ali, SM1
Ocio, EM1
Fernández-Lázaro, D1
San-Segundo, L1
López-Corral, L1
Corchete, LA1
Gutiérrez, NC1
Garayoa, M1
Paíno, T1
García-Gómez, A1
Delgado, M1
Montero, JC1
Díaz-Rodríguez, E1
Mateos, MV1
Pandiella, A1
Couto, S1
Wang, M1
Bjorklund, CC1
San-Miguel, JF1
Varga, C1
Xie, W1
Laubach, J1
Ghobrial, IM1
O'Donnell, EK1
Weinstock, M1
Paba-Prada, C1
Warren, D1
Maglio, ME1
Schlossman, R1
Munshi, NC1
Raje, N1
Weller, E1
Anderson, KC1
Mitsiades, CS1
Richardson, PG1
Salem, KZ1
Nishihori, T1
Kharfan-Dabaja, MA1
Horna, P1
Alsina, M1
Aagre, S1
Madabhavi, I1
Patel, A1
Anand, A1
Panchal, H1
Parikh, S1
Misawa, S1
Kuwabara, S1
Zhong, YP1
Chen, SL1
Nakazato, T2
Suzuki, K1
Mihara, A2
Sanada, Y2
Kakimoto, T1
Ninan, MJ1
Datta, YH1
Khaliq, W1
Uzoaru, I1
Konchanin, RP1
Sapiente, RA1
Egner, JR1
Wilson, SS1
Theodorescu, D1
Kashyap, R1
Kumar, R1
Kumar, S1
Grape, J1
Frosch, P1
Ito, C1
Aisa, Y1
Fukushima, T1
Nakamura, T1
Iwao, H1
Umehara, H1
Kawada, H1
Arima, N1
Drucker, L1
Uziel, O1
Tohami, T1
Shapiro, H1
Radnay, J1
Yarkoni, S1
Lahav, M1
Lishner, M1
Cisteró, B1
Sala, M1
Soler, A1
García, N1
Segarra, M1
Cid, MC1
Filella, X1
Aymerich, M1
Rozman, M1
Arenillas, L1
Esteve, J2
Montserrat, E2
Ribas, C1
Colleoni, G1
Almeida, M1
Duch, CR1
Ohashi, C1
Segreto, R1
Silva, MR1
del Giglio, A1
Weinschenker, P1
Manhani, AR1
Carbonell, AL1
Mitteldorf, CA1
Gaur, S1
Oo, TH1
Aish, LS1
Mansoor, S1
Terpos, E2
Rezvani, K1
Basu, S1
Milne, AE1
Rose, PE1
Scott, GL1
Rahemtulla, A1
Samson, D1
Apperley, JF1
Terrier, B1
Aouba, A1
Diop, S1
Clerc, J1
Vasiliu, V1
Munera, Y1
Hermine, O1
Katodritou, E1
Speletas, M1
Pouli, A1
Tsitouridis, J1
Zervas, K1
Pineda-Roman, M1
Bolejack, V1
Arzoumanian, V1
Anaissie, E1
van Rhee, F1
Zangari, M1
Walker, R1
Hollmig, K1
Shaughnessy, JD1
Epstein, J1
Krishna, S1
Crowley, J1
Patil, S1
Schwarer, A1
McLean, C1
Dytfeld, D1
Matuszak, M1
Lewandowski, K1
Komarnicki, M1
Perales, M1
Tuset, M1
Montoto, S1
Cobo, F1
Villela, L1
Rafel, M1
Nomdedeu, B1
Avigdor, A1
Raanani, P1
Levi, I1
Hardan, I1
Ben-Bassat, I1
Myers, B1
Grimley, C1
Crouch, D1
Dolan, G1

Reviews

8 reviews available for thalidomide and Plasmacytoma

ArticleYear
Acquired hemophilia A and plasma cell neoplasms: a case report and review of the literature.
    Journal of medical case reports, 2020, Oct-30, Volume: 14, Issue:1

    Topics: Aged; Factor VIII; Hemophilia A; Humans; Lenalidomide; Male; Multiple Myeloma; Plasmacytoma; Thalido

2020
Primary extramedullary plasmacytoma with diffuse lymph node involvement: a case report and review of the literature.
    Journal of medical case reports, 2019, May-22, Volume: 13, Issue:1

    Topics: Aged; Bortezomib; Dexamethasone; Fatigue; Humans; Lymph Nodes; Lymphadenopathy; Male; Plasma Cells;

2019
A case of extramedullary plasmablastic plasmacytoma successfully treated using a combination of thalidomide and dexamethasone and a review of the medical literature.
    Journal of clinical and experimental hematopathology : JCEH, 2013, Volume: 53, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Male; Middle Aged; Multiple M

2013
[Electrophysiologic aspects of Crow-Fukase (POEMS) syndrome--significance in early diagnosis and insights into the pathophysiology].
    Brain and nerve = Shinkei kenkyu no shinpo, 2008, Volume: 60, Issue:6

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Dia

2008
[New strategy of treatment for POEMS syndrome--autologous peripheral blood stem cell transplantation and thalidomide therapy].
    Brain and nerve = Shinkei kenkyu no shinpo, 2008, Volume: 60, Issue:6

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Com

2008
Post-transplant lymphoproliferative disorder presenting as multiple myeloma.
    American journal of hematology, 2010, Volume: 85, Issue:8

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy

2010
Rare bladder tumors: caveat emptor.
    Oncology (Williston Park, N.Y.), 2010, Volume: 24, Issue:9

    Topics: Abnormalities, Drug-Induced; Disease Progression; Female; Humans; Lenalidomide; Male; Multiple Myelo

2010
[Update on treatment of multiple myeloma: including myeloma kidney and molecular targeting drugs].
    Nihon Jinzo Gakkai shi, 2012, Volume: 54, Issue:5

    Topics: Boronic Acids; Bortezomib; Drug Design; Humans; Immunologic Factors; Kidney Neoplasms; Lenalidomide;

2012

Trials

1 trial available for thalidomide and Plasmacytoma

ArticleYear
Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease.
    British journal of haematology, 2007, Volume: 136, Issue:3

    Topics: Aged; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Moda

2007

Other Studies

40 other studies available for thalidomide and Plasmacytoma

ArticleYear
Daratumumab plus lenalidomide and dexamethasone for relapsed POEMS syndrome with bone plasmacytoma harboring 17p deletion.
    International journal of hematology, 2023, Volume: 117, Issue:3

    Topics: Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Plasmacytoma; PO

2023
Rare Pattern of Myelodysplastic Syndrome (MDS) with Serum Monoclonal Immunoglobulin: Case Report.
    Alternative therapies in health and medicine, 2023, Volume: 29, Issue:3

    Topics: Danazol; Dexamethasone; Humans; Male; Myelodysplastic Syndromes; Plasmacytoma; Thalidomide

2023
Successful treatment with pomalidomide and intrathecal injections for central nervous system plasmacytoma in a patient under haemodialysis.
    Journal of clinical pharmacy and therapeutics, 2020, Volume: 45, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophospha

2020
Hemophagocytic relapsed intramedullary plasmacytoma.
    International journal of hematology, 2020, Volume: 111, Issue:6

    Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bo

2020
Metastatic Intracerebral Plasmacytoma Treated with Radiation and Thalidomide, Dexamethasone with Cyclophosphamide Chemotherapy.
    World neurosurgery, 2017, Volume: 103

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cranial Irradiation; Cyclophosphami

2017
POEMS syndrome: a rare cause of exudative ascites and chronic peripheral neuropathy.
    BMJ case reports, 2017, Jun-20, Volume: 2017

    Topics: Adult; Ascites; Dexamethasone; Humans; Lenalidomide; Male; Myeloma Proteins; Paraproteinemias; Perip

2017
Metachronous solitary plasmacytoma.
    BMJ case reports, 2017, Oct-19, Volume: 2017

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Diphosphonates; Di

2017
[Extramedullary mediastinal plasmacytoma. Report of one case].
    Revista medica de Chile, 2017, Volume: 145, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Mediastinal Neoplasms; Mediastin

2017
Extramedullary Manifestation of Multiple Myeloma in the Oral Cavity.
    Archives of Iranian medicine, 2018, 12-01, Volume: 21, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease Progression; Fata

2018
Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma.
    European journal of haematology, 2019, Volume: 102, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplas

2019
Multiple myeloma presenting as plasmacytoma of the jaws showing prominent bone formation during chemotherapy.
    Dento maxillo facial radiology, 2013, Volume: 42, Issue:4

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; A

2013
Myeloma presenting during pregnancy.
    Hematological oncology, 2014, Volume: 32, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cesarean Section;

2014
Diplopia and variable ptosis as the sole initial findings in a case of orbital plasmacytoma and multiple myeloma.
    Seminars in ophthalmology, 2015, Volume: 30, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Biopsy; Blepharoptosis; Bone Marrow Cells; Cyclophosphamide; Dexa

2015
The successful treatment of a recurrent intracranial, dural-based plasmacytoma with lenalidomide.
    Journal of neuro-oncology, 2014, Volume: 119, Issue:1

    Topics: Aged; Angiogenesis Inhibitors; Brain Neoplasms; Female; Humans; Lenalidomide; Neoplasm Recurrence, L

2014
Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezom

2014
In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.
    Leukemia, 2015, Volume: 29, Issue:3

    Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis; Benzimidazoles; Cel

2015
Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.
    British journal of haematology, 2015, Volume: 169, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Female; Foll

2015
Primary plasmacytoma involving mediastinal lymph nodes: A diagnostic mimicry of primary mediastinal lymphoma.
    Hematology/oncology and stem cell therapy, 2016, Volume: 9, Issue:1

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Humans; Lenalidomide; Lymph Nodes; Male;

2016
Primary Plurifocal Extramedullary Plasmacytoma of Breast.
    The breast journal, 2016, Volume: 22, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Breast Neoplasms; Dexamethasone;

2016
[A clinical analysis of 25 cases of multiple myeloma complicated by extramedullary plasmacytomas].
    Zhonghua nei ke za zhi, 2009, Volume: 48, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason

2009
Refractory plasmablastic type myeloma with multiple extramedullary plasmacytomas and massive myelomatous effusion: remarkable response with a combination of thalidomide and dexamethasone.
    Internal medicine (Tokyo, Japan), 2009, Volume: 48, Issue:20

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Male; Multiple Myeloma;

2009
Solitary extramedullary plasmacytoma of the bladder: a case report and literature.
    Oncology (Williston Park, N.Y.), 2010, Volume: 24, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cystoscopy; Dexamethasone; Humans; Len

2010
Cranial nerve palsy in multiple myeloma and solitary plasmacytoma.
    Asia-Pacific journal of clinical oncology, 2010, Volume: 6, Issue:4

    Topics: Abducens Nerve Diseases; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th

2010
[Papular drug eruption along the lines of Blaschko caused by lenalidomide].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2011, Volume: 62, Issue:8

    Topics: Antineoplastic Agents; Diagnosis, Differential; Drug Eruptions; Humans; Leg Dermatoses; Lenalidomide

2011
Lenalidomide is active for extramedullary disease in refractory multiple myeloma.
    Annals of hematology, 2012, Volume: 91, Issue:3

    Topics: Aged, 80 and over; Antineoplastic Agents; Humans; Lenalidomide; Male; Multiple Myeloma; Plasmacytoma

2012
Rapid response of plasmacytomas to lenalidomide plus low-dose dexamethasone therapy in a patient with relapsed multiple myeloma.
    American journal of hematology, 2011, Volume: 86, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Middle

2011
Thalidomide down-regulates transcript levels of GC-rich promoter genes in multiple myeloma.
    Molecular pharmacology, 2003, Volume: 64, Issue:2

    Topics: Adenomatous Polyposis Coli Protein; Antigens, CD; DNA-Binding Proteins; GC Rich Sequence; Humans; Im

2003
[Thalidomide in the treatment of recurrent plasmocitomas in an HIV-infected patient].
    Medicina clinica, 2004, Apr-24, Volume: 122, Issue:15

    Topics: HIV Infections; Humans; Male; Middle Aged; Plasmacytoma; Recurrence; Thalidomide

2004
Response to thalidomide in multiple myeloma: impact of angiogenic factors.
    Cytokine, 2004, May-21, Volume: 26, Issue:4

    Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Angiogenic Proteins; Cytokines; Female; Human

2004
Response of plasmacytomas to low-dose thalidomide in a patient with refractory multiple myeloma.
    Acta oncologica (Stockholm, Sweden), 2004, Volume: 43, Issue:2

    Topics: Angiogenesis Inhibitors; Humans; Male; Mandibular Neoplasms; Middle Aged; Multiple Myeloma; Plasmacy

2004
Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide.
    Southern medical journal, 2005, Volume: 98, Issue:2

    Topics: Antineoplastic Agents; Asthenia; Biopsy; Bone Marrow Cells; Boronic Acids; Bortezomib; Female; Human

2005
Gastric relapse of solitary bone plasmacytoma.
    American journal of clinical oncology, 2005, Volume: 28, Issue:3

    Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combin

2005
Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma.
    European journal of haematology, 2005, Volume: 75, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clone Cells; Disease Progression; Dose-Respons

2005
Thyroid gland plasmacytoma with a dramatic and persistent complete response under thalidomide and dexamethasone-associated treatment.
    Leukemia & lymphoma, 2006, Volume: 47, Issue:7

    Topics: Aged; Antineoplastic Agents, Hormonal; Dexamethasone; Female; Humans; Immunosuppressive Agents; Mult

2006
Successful treatment of extramedullary plasmacytoma of the cavernous sinus using a combination of intermediate dose of thalidomide and dexamethasone.
    Acta haematologica, 2007, Volume: 117, Issue:1

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cavernous Sinus; Dexamethas

2007
Urinary cytology in multiple myeloma.
    Cytopathology : official journal of the British Society for Clinical Cytology, 2008, Volume: 19, Issue:2

    Topics: Acute Kidney Injury; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Fat

2008
Bortezomib in combination with thalidomide and dexamethasone--a successful treatment regimen in refractory extramedullary multiple myeloma.
    Annals of hematology, 2008, Volume: 87, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Ma

2008
Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas.
    British journal of haematology, 2001, Volume: 113, Issue:2

    Topics: Aged; Bone Marrow Cells; Connectin; Drug Administration Schedule; Female; Humans; Immunosuppressive

2001
Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma.
    Leukemia & lymphoma, 2001, Volume: 42, Issue:4

    Topics: Adult; Bone Marrow; Bone Marrow Neoplasms; Brain Neoplasms; Disease Progression; Humans; Male; Middl

2001
Lack of response to thalidomide in plasmacytomas.
    British journal of haematology, 2001, Volume: 115, Issue:1

    Topics: Humans; Immunosuppressive Agents; Male; Middle Aged; Paraproteins; Plasmacytoma; Thalidomide; Treatm

2001